Experienced entrepreneurs with extensive biotech and immunotherapy experience.

Emil Pot
Frederico Grego
Kees Leenhouts

>20 years of experience in technology transfer and biotech start-up companies. Co-founder of ActoGenix, IP expert at NLO & BD Oncode, LL.M. EU Patent Attorney.

>20 years of senior management experience in Allergy sector. Executive VP LETI Pharma, CEO Spire Bioventures, GM at nLife Therapeutics & CBO Cytovation AS. Economist, MBA

>25 years of Pharma/Biotech R&D experience in vaccine tech development. ​Co-founder & CSO of Mucosis, Inventor of bacterial particle technology. Biotechnologist, PhD

Poul Sørensen
Steven Glazer
Christophe Saillez
VP Regulatory

>25 years of Pharma/Biotech R&D experience in immunotherapy. Senior Management at ALK, Stallergenes, LEO Pharma, Micromet, Pharmacia. Professor of Biomedicine, PhD

>25 yrs senior management experience in medical and regulatory affairs including Novo Nordisk, Maxygen, Bioinvent, Idogen, Immunicum, Rhovac. MD, PhD.

25 yrs Pharma/Biotech regulatory, quality and CMC experience, including GSK, Actobio Therapeutics, Janssen Vaccines.

Biochem. Engineer.


>25 years of Pharma/Biotech R&D experience in vaccine tech development. ​Co-founder & CSO of Mucosis, Inventor of bacterial particle technology.

Biotechnologist, PhD

Cillian King
Chairman of the board
Flemming Steen Jensen
Board member
Mariëtte van der Velden - Roesink

Investment Manager at Swanbridge Capital. Joined the Board of Allero Therapeutics in April 2019. Background in Molecular Biology (VU University and MIT) & PhD in Molecular Neuroscience (VU University). Prior to Swanbridge he worked as a consultant for early-stage ventures in the Life Sciences industry. ​

>30 years of senior management experience at leading pharmaceutical companies (ALK, Novo Nordisk, among others), with particular focus on supply chain management, Manufacturing, CMC, QA & strategy. participated in several advisory boards and board of directors in various small Danish life science companies. He is currently Senior Vice President of Product Supply at Ascendis Pharma.

Mariëtte has over 18 years of business experience (S&M, BD) at pioneering biotech companies (e.g. Genzyme, Uniqure), followed by over 6 years of venture capital fund management and participated in several board of directors in life science companies. She is currently Managing Partner at Curie Capital. ​


Allero has put together a Scientific Advisory Board established with world leading key opinion leaders that has supported and challenged the founding team since the very beginning of the project. The SAB includes leading experts in Immunology and immune mediated disorders with particular focus on Celiac Disease and Allergy, and Clinical Development. ​